Le Henanff Anne, Giraudeau Bruno, Baron Gabriel, Ravaud Philippe
Institut National de la Santé et de la Recherche Médicale (INSERM) U738, Paris, France.
JAMA. 2006 Mar 8;295(10):1147-51. doi: 10.1001/jama.295.10.1147.
Noninferiority and equivalence trials aim to show that the experimental treatment is not clinically worse than (noninferior) or clinically similar to (equivalent) a control active treatment. These study objectives imply particular planning and analysis.
To assess the methodologic quality of reports of randomized controlled trials of noninferiority and equivalence.
We searched MEDLINE and the Cochrane Central Register of Controlled Trials for reports of randomized controlled trials of noninferiority and equivalence hypotheses published between January 1, 2003, and December 31, 2004.
Data extracted by use of a standardized form involved assessment of choice of noninferiority or equivalence margins, sample size calculation, sets of patients analyzed, method of statistical testing and reporting results, and conclusions.
A total of 162 reports were included in the analysis (116 reports of noninferiority and 46 of equivalence). The margin defining noninferiority or equivalence was described in most reports (156 [96.3%]), with justification of the margin in only 33 (20.4%). Almost one quarter of the reports (35 [21.6%]) did not describe a sample size calculation, and an additional 11 (6.8%) did not take into account a prespecified noninferiority or equivalence margin. Less than half of the reports (69 [42.6%]) described both an intent-to-treat (ITT; all randomized patients are included in the analysis) or modified ITT (patients who never received treatment are excluded) and per-protocol (patients who did not complete the treatment are excluded) analysis, and only about half of those (39 [56.5%]) described both types of results. Results were displayed with confidence intervals in 136 reports (84.0%). Only 33 articles (20.3%) fulfilled reporting requirements specific to noninferiority and equivalence trials, 4 of them (12.1%) with misleading conclusions.
Reporting of noninferiority and equivalence trials has important deficiencies: absence of noninferiority or equivalence margin, only an ITT (or a per-protocol) analysis performed, and results not adequately reported. Moreover, even for articles fulfilling these requirements, conclusions are sometimes misleading.
非劣效性试验和等效性试验旨在表明试验性治疗在临床上不比对照活性治疗差(非劣效性)或与对照活性治疗相似(等效性)。这些研究目标意味着需要特殊的设计和分析。
评估非劣效性和等效性随机对照试验报告的方法学质量。
我们检索了MEDLINE和Cochrane对照试验中央注册库,以查找2003年1月1日至2004年12月31日期间发表的关于非劣效性和等效性假设的随机对照试验报告。
使用标准化表格提取的数据包括对非劣效性或等效性界值的选择、样本量计算、分析的患者组、统计检验方法和报告结果以及结论的评估。
共有162份报告纳入分析(116份非劣效性报告和46份等效性报告)。大多数报告(156份[96.3%])描述了定义非劣效性或等效性的界值,其中只有33份(20.4%)对界值进行了说明。近四分之一的报告(35份[21.6%])未描述样本量计算,另有11份(6.8%)未考虑预先设定的非劣效性或等效性界值。不到一半的报告(69份[42.6%])描述了意向性分析(ITT;所有随机分组的患者均纳入分析)或改良意向性分析(从未接受治疗的患者被排除)以及符合方案分析(未完成治疗的患者被排除),并且其中只有约一半(39份[56.5%])同时描述了两种类型的结果。136份报告(84.0%)以置信区间展示结果。只有33篇文章(20.3%)符合非劣效性和等效性试验的特定报告要求,其中4篇(12.1%)得出了误导性结论。
非劣效性和等效性试验的报告存在重要缺陷:缺乏非劣效性或等效性界值、仅进行了意向性分析(或符合方案分析)以及结果报告不充分。此外,即使对于符合这些要求的文章,结论有时也具有误导性。